We propose an alternative mechanism of tumor clearance providing the possibility to therapy relapsed or refractory NHL in the second- or third-line setting solely implying BCR sequencing to identify the disease-causing B cell clone. This evidence concerns the gene BCR and non-Hodgkin lymphoma.